Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KETOCOGNITION
NCT03657537Phase 1Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Sep 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 3-hydroxybutyrate in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Cognitive composite score (global score). Started Sep 2018; status: completed.
02
Drugs
3-hydroxybutyrate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03657537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657537.